Needham Maintains Buy on ResMed, Raises Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has maintained a Buy rating on ResMed (NYSE:RMD) and increased the price target from $180 to $215.
January 25, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson reaffirmed a Buy rating on ResMed and raised the price target to $215, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100